Biologics arrive in COPD
COPD is moving from a small-molecule-only category to one with biologic options for selected phenotypes.
COPD has historically been a small-molecule, inhaler-driven category. The arrival of biologics for selected phenotypes is the most material change in routine pulmonology care in years - the question is which patients actually get to one.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is obstructive sleep apnea?
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.